May 10, 2007 (Las Vegas) — Rituximab can be safely infused using a rapid 90-minute protocol in patients with non-Hodgkin's lymphoma, according to a presentation made at the annual meeting of the ...

A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

Medicare Part B (medical insurance) may cover Rituxan (rituximab) infusions. This is because medical professionals typically administer the medication in a medical setting on an outpatient basis.

Last month, a retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS) ...

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...

Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...

THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...

Serious infusion-related reactions can happen during your infusion or within 24 hours after your infusion of Rituxan. Your healthcare provider should give you medicines before your infusion of Rituxan ...

Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor ...

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

NEW ORLEANS -- In a randomized comparison, rituximab (Rituxan) proved non-inferior to cyclosporine for the treatment of idiopathic membranous nephropathy, a researcher reported here. Preliminary ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...